Bioventus Inc. Class A Common Stock BVS
$14.26
+2.66%
at last close
Analyst Consensus
- Consensus Rating
- Buy (3 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $15.00
- Implied Upside
- +5.2%
- Price Target Range
- $14.00 – $16.00
- Analysts (12 mo)
- 3
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-06-30 | Barrington ResearchMichael Petusky |
Maintains | Outperform | $14 |
| 2026-06-16 | Canaccord GenuityCaitlin Cronin |
Maintains | Buy | $15 |
| 2026-05-22 | Barrington ResearchMichael Petusky |
Maintains | Outperform | $14 |
| 2026-03-06 | Barrington ResearchMichael Petusky |
Maintains | Outperform | $13 → $14 |
| 2026-03-06 | Craig-HallumAlexander Nowak |
Maintains | Buy | $15 → $16 |
| 2026-02-09 | Barrington ResearchMichael Petusky |
Initiates coverage on | Outperform | $13 |
| 2025-07-07 | Cantor FitzgeraldRoss Osborn |
Initiates coverage on | Overweight | $12 |
| 2025-03-17 | Canaccord GenuityCaitlin Cronin |
Maintains | Buy | $15 |
| 2024-12-17 | JP MorganRobbie Marcus |
Upgrades | Underweight → Neutral | $12 → $13 |
| 2024-11-06 | Canaccord GenuityWilliam Plovanic |
Maintains | Buy | $12 → $15 |
| 2024-09-27 | Craig-HallumAlexander Nowak |
Maintains | Buy | $12 → $17 |
| 2024-08-13 | Canaccord GenuityWilliam Plovanic |
Maintains | Buy | $8 → $12 |
| 2024-08-07 | Craig-HallumAlexander Nowak |
Maintains | Buy | $9 → $12 |
| 2024-05-08 | Canaccord GenuityWilliam Plovanic |
Maintains | Buy | $7 → $8 |
| 2024-03-13 | Craig-HallumAlexander Nowak |
Maintains | Buy | $6 → $9 |
| 2023-12-07 | Canaccord GenuityWilliam Plovanic |
Upgrades | Hold → Buy | $4 → $7 |
| 2023-04-03 | Craig-HallumAlexander Nowak |
Maintains | Hold | $10 → $5 |
| 2022-11-30 | Goldman SachsAmit Hazan |
Maintains | Neutral | $13 → $3 |
| 2022-11-22 | Craig-HallumAlexander Nowak |
Downgrades | Buy → Hold | — |
| 2022-11-10 | Morgan StanleyDrew Ranieri |
Maintains | Overweight | $11 → $5 |
| 2022-11-09 | Canaccord GenuityKyle Rose |
Downgrades | Buy → Hold | — |
| 2022-11-09 | JP MorganRobbie Marcus |
Downgrades | Overweight → Underweight | — |
| 2022-10-11 | Morgan StanleyDrew Ranieri |
Maintains | Overweight | $12 → $11 |
| 2022-09-07 | Goldman SachsAmit Hazan |
Maintains | Neutral | $15 → $13 |
| 2022-08-12 | Morgan StanleyDrew Ranieri |
Maintains | Overweight | $11 → $12 |
| 2022-05-12 | Morgan StanleyDrew Ranieri |
Maintains | Overweight | $18 → $11 |
| 2022-03-21 | Goldman SachsAmit Hazan |
Maintains | Neutral | $19 → $17 |
| 2022-03-15 | Craig-HallumAlexander Nowak |
Initiates coverage on | Buy | $30 |
| 2022-03-11 | Morgan StanleyDrew Ranieri |
Maintains | Overweight | $20 → $18 |
| 2021-11-15 | Morgan StanleyDrew Ranieri |
Reinstates | Overweight | $20 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $14.26
- Market Cap
- $1.20 billion
- 52-Week Range
- $5.81 – $15.89
- Average Volume
- 818K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.